Strategies to overcome resistance to immune checkpoint blockade in lung cancer
- PMID: 33684660
- DOI: 10.1016/j.lungcan.2021.02.035
Strategies to overcome resistance to immune checkpoint blockade in lung cancer
Abstract
The adoption of Immune checkpoint inhibitors (ICIs) allowed the achievement of impressive long-term survival results in non-small cell lung cancer (NSCLC), but most patients develop resistance to ICI treatment over time. Resistance to ICIs is mediated by several complex mechanisms affecting, but not limited to, tumour cell-intrinsic alterations and the tumour microenvironment. The possibility of modulating the immune response by interfering with specific alternative immune receptors, pathways and mediators might provide additional strategies to delay or prevent the development of resistance. Therefore, a greater in-depth investigation and understanding of these mechanisms aims to identify novel classes of immune targets and subsequently to evaluate potential new strategies for overcoming resistance, which will be assessed in this review.
Keywords: Adoptive cell therapy; Gut microbiota; Immunotherapy; Resistance mechanisms; TIGIT; Tumour microenvironment.
Copyright © 2021 Elsevier B.V. All rights reserved.
Similar articles
-
The cutting-edge progress of immune-checkpoint blockade in lung cancer.Cell Mol Immunol. 2021 Feb;18(2):279-293. doi: 10.1038/s41423-020-00577-5. Epub 2020 Nov 11. Cell Mol Immunol. 2021. PMID: 33177696 Free PMC article. Review.
-
Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.J Control Release. 2021 Apr 10;332:109-126. doi: 10.1016/j.jconrel.2021.02.002. Epub 2021 Feb 8. J Control Release. 2021. PMID: 33571549 Review.
-
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies.J Clin Oncol. 2022 Feb 20;40(6):598-610. doi: 10.1200/JCO.21.01845. Epub 2022 Jan 5. J Clin Oncol. 2022. PMID: 34985992 Review.
-
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05. Oncologist. 2019. PMID: 30819829 Free PMC article. Review.
-
Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer.Front Immunol. 2023 Feb 8;14:1127071. doi: 10.3389/fimmu.2023.1127071. eCollection 2023. Front Immunol. 2023. PMID: 36845142 Free PMC article. Review.
Cited by
-
Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy - single institute experience.Radiol Oncol. 2021 Nov 19;55(4):482-490. doi: 10.2478/raon-2021-0044. Radiol Oncol. 2021. PMID: 34821136 Free PMC article.
-
[Research Progress of Immune Checkpoint TIGIT in Lung Cancer Immunotherapy].Zhongguo Fei Ai Za Zhi. 2022 Nov 20;25(11):819-827. doi: 10.3779/j.issn.1009-3419.2022.102.45. Zhongguo Fei Ai Za Zhi. 2022. PMID: 36419396 Free PMC article. Chinese.
-
[Advances of Immunotherapy Resistance and Coping Strategies in Non-small Cell Lung Cancer].Zhongguo Fei Ai Za Zhi. 2023 Jan 20;26(1):66-77. doi: 10.3779/j.issn.1009-3419.2023.102.03. Zhongguo Fei Ai Za Zhi. 2023. PMID: 36792083 Free PMC article. Review. Chinese.
-
M1 macrophage-related gene model for NSCLC immunotherapy response prediction.Acta Biochim Biophys Sin (Shanghai). 2024 Mar 25;56(3):379-392. doi: 10.3724/abbs.2023262. Acta Biochim Biophys Sin (Shanghai). 2024. PMID: 38379417 Free PMC article.
-
Construction of a B cell-related gene pairs signature for predicting prognosis and immunotherapeutic response in non-small cell lung cancer.Front Immunol. 2022 Oct 27;13:989968. doi: 10.3389/fimmu.2022.989968. eCollection 2022. Front Immunol. 2022. PMID: 36389757 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
